Aurinia Pharmaceuticals Inc (AUPH)

[Lunacy_John Galt]

Jess, you and I along with a couple others have been pretty consistent in our belief the last couple years that we would see an even more compelling data readout than the PH2B trial. There were some considerations to seriously consider. Mostly for me, was more pts enrolled that had previous MMF use. I wasn't as worried by a more diversified group, but it was something to consider.

End of the day, we felt the Aurinia team knew what they were doing when they put together the trial protocol. It doesn't often play out exactly the way they draw it up with these trials, but it sure feels nice knowing we assumed correctly. The efficacy is strong, but the safety data blew everyone away. Only allowing sites that could provide reasonable SOC, was the game changer.

Cheers!